Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages post-meal glucose spikes when taken right before meals. Hypoglycemia risk increases if meals are delayed, skipped, or low in carbohydrates. Suitable for elderly patients and those with severe sulfur or sulfonylurea allergies, it can be used alone or combined with biguanides.

Repaglinide is absorbed rapidly, reaching peak blood levels within an hour, making it suitable for pre-meal usage. It's mainly metabolized by the liver, with a small amount processed by the kidneys, necessitating caution in patients with renal insufficiency. Its major side effect is hypoglycemia, and its effectiveness can decline after initial improvements. Some drugs may enhance its action by altering its metabolism or displacing it from plasma protein-binding sites.

Nateglinide promotes insulin secretion swiftly but less enduringly than other oral antidiabetic agents. It effectively reduces post-meal glycemic spikes when taken shortly before meals. Metabolized primarily by hepatic CYPs, it should be used cautiously in patients with liver insufficiency. Certain drugs may reduce the glucose-lowering effect of nateglinide or increase the risk of hypoglycemia. Unlike other insulin secretagogues, nateglinide may lead to fewer hypoglycemic episodes but has similar secondary failure rates.

Du chapitre 25:

article

Now Playing

25.12 : Oral Hypoglycemic Agents: Glinides

Insulin and Hypoglycemic Drugs

63 Vues

article

25.1 : L’homéostasie du glucose : régulation de la glycémie

Insulin and Hypoglycemic Drugs

937 Vues

article

25.2 : Homéostasie du glucose : îlots pancréatiques et sécrétion d’insuline

Insulin and Hypoglycemic Drugs

685 Vues

article

25.3 : L’insuline : le récepteur et les voies de signalisation

Insulin and Hypoglycemic Drugs

736 Vues

article

25.4 : Physiopathologie du diabète

Insulin and Hypoglycemic Drugs

533 Vues

article

25.5 : Diabète : symptômes, diagnostic et complications

Insulin and Hypoglycemic Drugs

396 Vues

article

25.6 : Diabète : prise en charge et pharmacothérapie

Insulin and Hypoglycemic Drugs

156 Vues

article

25.7 : L’insuline : biosynthèse, chimie et préparation

Insulin and Hypoglycemic Drugs

176 Vues

article

25.8 : Formulations d’insuline : types et administration

Insulin and Hypoglycemic Drugs

85 Vues

article

25.9 : Insuline : schéma posologique et effets indésirables

Insulin and Hypoglycemic Drugs

71 Vues

article

25.10 : Agents hypoglycémiants oraux : Sulfonylurées

Insulin and Hypoglycemic Drugs

83 Vues

article

25.11 : Hypoglycémiants oraux : Biguanides et Glitazones

Insulin and Hypoglycemic Drugs

89 Vues

article

25.13 : Agents hypoglycémiants oraux : inhibiteurs de la α-glucosidase

Insulin and Hypoglycemic Drugs

66 Vues

article

25.14 : Agonistes des récepteurs de type glucagon

Insulin and Hypoglycemic Drugs

121 Vues

article

25.15 : Inhibiteurs de la dipeptidil peptidase 4

Insulin and Hypoglycemic Drugs

68 Vues

See More

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.